All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Post-remission therapy for patients not proceeding to HSCT

Dec 27, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute myeloid leukemia.

Bookmark this article

During the AML Hub Steering Committee meeting, held in November 2023, key opinion leaders met to discuss postremission therapy for patients not proceeding to hematopoietic stem cell transplantation. This recorded session was chaired by Gail Roboz and featured Charles Craddock, Gert Ossenkoppele, Gunnar Juliusson, Jefferey Lancet, Jorge Sierra, Roland Walter, and Yasushi Miyazaki.

Post-remission therapy for patients not proceeding to HSCT

The steering committee discussed current induction strategies, how to optimize remission rates, and the impact of measurable residual disease on treatment decisions. They also considered how various global centers manage patients with NPM1-mutated acute myeloid leukemia in first morphological measurable residual disease-negative remission by polymerase chain reaction who are eligible for transplantation.


Subscribe to get the best content related to AML delivered to your inbox